Revolution Medicines' Rasonque Becomes First FDA-Approved RAS-Targeting Therapy for Metastatic Pancreatic Cancer
First Broad RAS-Targeted Therapy
On August 26, 2026, the U.S. FDA granted full approval to Rasonque (active ingredient: daraxonrasib) developed by Revolution Medicines (RVMD). The indication is for adult patients with metastatic pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy or for whom multi-agent systemic therapy is difficult. It is a once-daily oral therapy at the approved stage. Daraxonrasib is a non-covalent, RAS(ON)-selective, multi-selective triple complex inhibitor that blocks the binding between active wild-type and mutant RAS proteins and downstream effectors. It can be used without a companion diagnostic, regardless of RAS mutation status, offering a broader patient population than existing precision therapies limited to specific KRAS mutations.
A Phase 3 Trial That Changed Survival
The approval was based on the global Phase 3 RASolute 302 (NCT06625320) trial, which randomly assigned 500 adults with previously treated metastatic pancreatic ductal adenocarcinoma to receive either daraxonrasib 300mg or investigator-choice cytotoxic chemotherapy. The median overall survival in the overall patient population was 13.2 months versus 6.7 months, with a hazard ratio of 0.40, indicating a 60% reduction in the risk of death (p < 0.0001). The median progression-free survival also improved to 7.2 months versus 3.6 months, with a hazard ratio of 0.49. The time to deterioration in quality of life was 5.7 months versus 2.6 months, and time to worsening pain was 9.2 months versus 3.8 months, demonstrating both survival extension and reduced symptom burden.
Fast-Track Review and Commercial Implications
The FDA granted Rasonque Breakthrough Therapy and Orphan Drug designations, and applied Priority Review and a National Priority Review Voucher, resulting in approval 6.5 months earlier than the Prescription Drug User Fee Act (PDUFA) deadline. Starting on the day of approval, U.S. prescriptions were made available following a National Priority Voucher selection in October 2025 and an Expanded Access Program initiation in May 2026. No advisory committee vote was held. The EMA is conducting a phased review under its Oncology Medicines Pathfinder, granted Orphan Drug designation, and included the application in the international joint review system, Project Orbis. This pathway signifies more than just early approval—it marks Revolution Medicines' transition from a research-stage biotech to a commercial-stage company with its own marketed product.
Market and Competitive Landscape
The global pancreatic cancer treatment market was estimated at approximately USD 3.45 billion in 2025, with around 67,000 new cases of pancreatic cancer diagnosed annually in the U.S., 90–95% of which are pancreatic ductal adenocarcinoma. The current first-line standard includes FOLFIRINOX, gemcitabine plus nab-paclitaxel, or NALIRIFOX (Onivyde, liposomal irinotecan-based). Second-line therapies typically include Onivyde, 5-FU, leucovorin, or gemcitabine-based regimens. Rasonque competes directly with these intravenous chemotherapies but offers differentiation through oral administration, broad RAS inhibition, and overall survival improvement. Future competitive factors include Revolution Medicines' Phase 1/2 KRAS G12D inhibitor zolodarnasib and the Phase 3 RASolute 303 and 304 trials evaluating daraxonrasib in first-line metastatic and adjuvant settings, with market expansion dependent on the success of these subsequent trials.
Rasonque redefined the clinical standard for second-line treatment of metastatic pancreatic cancer by achieving a median overall survival of 13.2 months versus 6.7 months with chemotherapy, with a hazard ratio of 0.40. The global pancreatic cancer treatment market was approximately USD 3.45 billion in 2025, and 90–95% of the 67,000 new U.S. pancreatic cancer cases annually are pancreatic ductal adenocarcinoma, making the label approval without companion diagnostics commercially broad. In the short term, Rasonque is expected to capture market share from Onivyde-based regimens, gemcitabine plus nab-paclitaxel, and FOLFOX-based therapies, transforming Revolution Medicines into a revenue-generating commercial-stage company. Mid- to long-term value will be determined by the expansion of RASolute 303 and 304 into first-line and adjuvant settings, the KRAS G12D combination strategy of zolodarnasib in Phase 1/2 trials, and the regulatory precedent it sets for broad RAS-targeting platform expansion into lung and colorectal cancers.
Source: FDA Drug Approvals (rss)